ScreenerHero

BTMD biote Corp.

NAS · US · Healthcare · Medical Care Facilities · biote.com
1.110USD-2.63%Mkt Cap: 37.63M $P/E: 7.93

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men …

Industry Peers

Medical Care Facilities
Screen all
HCA
HCA Healthcare, Inc.
$97.43BUSDP/E 14.7
FRE
Fresenius SE & Co. KGaA
$26.50BUSDP/E 15.6
THC
Tenet Healthcare Corporation
$20.92BUSDP/E 10.1
EHC
Encompass Health Corporation
$12.08BUSDP/E 20.5
DVA
DaVita Inc.
$11.35BUSDP/E 14.9
FME
Fresenius Medical Care AG
$10.92BUSDP/E 11.3
FMS
Fresenius Medical Care AG
$11.01BUSDP/E 10.7
UHS
Universal Health Services, Inc.
$10.29BUSDP/E 7.1
ENSG
The Ensign Group, Inc.
$9.86BUSDP/E 26.5
PACS
PACS Group, Inc.
$6.84BUSDP/E 25.3
CHE
Chemed Corporation
$6.55BUSDP/E 25.2
OPCH
Option Care Health, Inc.
$4.65BUSDP/E 23.5
CON
Concentra Group Holdings Parent, Inc.
$4.64BUSDP/E 23.5
LFST
LifeStance Health Group, Inc.
$4.60BUSDP/E 93.2
MCOV-B
Medicover AB (publ)
$3.78BUSDP/E 42.6
NHC
National HealthCare Corporation
$3.46BUSDP/E 24.9
ACHC
Acadia Healthcare Company, Inc.
$2.72BUSD
AVAH
Aveanna Healthcare Holdings Inc.
$2.69BUSDP/E 9.8
GRDN
Guardian Pharmacy Services, Inc.
$2.58BUSDP/E 39.5
BKD
Brookdale Senior Living Inc.
$2.57BUSD
HeadlineSourceTime
Older
Biote Corp (BTMD) (Q2 2026) Earnings Call Highlights: Navigating Recall Challenges and ...

Despite a 9.5% revenue decline and revised guidance, Biote Corp (BTMD) focuses on operational recovery, supply normalization, and inorganic growth opportunities.

GuruFocus.com
biote Corp. (BTMD) Reports Break-Even Earnings for Q2

biote Corp. (BTMD) delivered earnings and revenue surprises of -100.00% and -5.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
biote Q2 Earnings Call Highlights

biote (NASDAQ:BTMD) reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said supply conditions have since normalized and should support sequential improvement in the second half

MarketBeat